SmithKline Beckman Corp. posted second-quarter earnings of...
SmithKline Beckman Corp. posted second-quarter earnings of $98.7 million, down 25% from the same 1987 quarter. A major reason for the sharp decline was lower-than-expected sales of the Philadelphia-based pharmaceutical company’s two major drugs, Tagamet and Dyazide, SmithKline said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
